Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab.

Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, Kamoi K, Nakai K, Mizuki N, Ohguro N; Ocular Behçet Disease Research Group of Japan.

Jpn J Ophthalmol. 2014 Mar;58(2):120-30. doi: 10.1007/s10384-013-0294-0. Epub 2014 Jan 31.

PMID:
24482146
[PubMed - indexed for MEDLINE]
2.

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.

Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M.

Ophthalmology. 2014 Oct;121(10):1877-84. doi: 10.1016/j.ophtha.2014.04.042. Epub 2014 Jun 18.

PMID:
24950593
[PubMed - indexed for MEDLINE]
3.

Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.

Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S58-63. Epub 2011 Sep 27.

PMID:
21968238
[PubMed - indexed for MEDLINE]
4.

Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.

Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, Mochizuki M.

Jpn J Ophthalmol. 2014 Jan;58(1):75-80. doi: 10.1007/s10384-013-0283-3. Epub 2013 Oct 16.

PMID:
24129677
[PubMed - indexed for MEDLINE]
5.

Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.

Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka H.

Br J Ophthalmol. 2013 Mar;97(3):338-42. doi: 10.1136/bjophthalmol-2012-302515. Epub 2013 Jan 12.

PMID:
23314623
[PubMed - indexed for MEDLINE]
6.

Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y.

Jpn J Ophthalmol. 2012 Nov;56(6):536-43. doi: 10.1007/s10384-012-0182-z. Epub 2012 Oct 2.

PMID:
23053631
[PubMed - indexed for MEDLINE]
7.

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.

Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. Epub 2007 Jun 7.

PMID:
17554481
[PubMed - indexed for MEDLINE]
8.

Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.

Interlandi E, Leccese P, Olivieri I, Latanza L.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S58-62. Epub 2014 Jul 8.

PMID:
25005224
[PubMed - indexed for MEDLINE]
9.

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.

Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ.

Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):63-70.

PMID:
17558830
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.

Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M.

Arthritis Res Ther. 2012 May 1;14(3):R99. doi: 10.1186/ar3824.

PMID:
22546542
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.

Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F.

Rheumatology (Oxford). 2007 Jul;46(7):1161-4. Epub 2007 May 3.

PMID:
17478466
[PubMed - indexed for MEDLINE]
Free Article
12.

Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.

Takeuchi M, Asukata Y, Kawagoe T, Ito N, Nishide T, Mizuki N.

Ocul Immunol Inflamm. 2012 Jun;20(3):193-7. doi: 10.3109/09273948.2012.665124. Epub 2012 Apr 9.

PMID:
22486264
[PubMed - indexed for MEDLINE]
13.

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G.

J Rheumatol. 2004 Jul;31(7):1362-8.

PMID:
15229958
[PubMed - indexed for MEDLINE]
14.

Induction of regulatory T cells by infliximab in Behcet's disease.

Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M.

Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):476-84. doi: 10.1167/iovs.10-5916.

PMID:
20861484
[PubMed - indexed for MEDLINE]
Free Article
15.

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP.

Rheumatology (Oxford). 2011 Mar;50(3):593-7. doi: 10.1093/rheumatology/keq366. Epub 2010 Nov 21.

PMID:
21097877
[PubMed - indexed for MEDLINE]
Free Article
16.

[Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].

Tanaka H, Sugita S, Yamada Y, Kawaguchi T, Iwanaga Y, Kamoi K, Yokota M, Takase H, Mochizuki M.

Nihon Ganka Gakkai Zasshi. 2010 Feb;114(2):87-95. Japanese.

PMID:
20187505
[PubMed - indexed for MEDLINE]
17.

Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.

Tognon S, Graziani G, Marcolongo R.

Ann N Y Acad Sci. 2007 Sep;1110:474-84.

PMID:
17911463
[PubMed - indexed for MEDLINE]
18.

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.

Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, Ohno S, Ishida S.

Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1081-7. doi: 10.1007/s00417-011-1908-1. Epub 2012 Jan 11.

PMID:
22234352
[PubMed - indexed for MEDLINE]
19.

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.

Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A.

Arthritis Rheum. 2005 Aug;52(8):2478-84.

PMID:
16052571
[PubMed - indexed for MEDLINE]
Free Article
20.

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.

Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y.

Rheumatol Int. 2011 Feb;31(2):243-5. doi: 10.1007/s00296-009-1178-y. Epub 2009 Oct 9.

PMID:
19816689
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk